JSPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JSPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Jasper Therapeutics's total free cash flow for the months ended in Dec. 2024 was $-21.23 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-63.15 Mil.
Jasper Therapeutics's Free Cash Flow per Share for the months ended in Dec. 2024 was $-1.41. Its free cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.34.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 48.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.
During the past 5 years, Jasper Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 53.00% per year. The lowest was 48.50% per year. And the median was 50.75% per year.
The historical data trend for Jasper Therapeutics's Free Cash Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jasper Therapeutics Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Free Cash Flow | -18.27 | -36.11 | -46.43 | -52.33 | -63.15 |
Jasper Therapeutics Quarterly Data | ||||||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Free Cash Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-16.71 | -15.76 | -11.84 | -14.33 | -21.23 |
Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.
Jasper Therapeutics's Free Cash Flow for the fiscal year that ended in Dec. 2024 is calculated as
Free Cash Flow (A: Dec. 2024 ) | = | Cash Flow from Operations | + | Capital Expenditure |
= | -62.602 | + | -0.552 | |
= | -63.15 |
Jasper Therapeutics's Free Cash Flow for the quarter that ended in Dec. 2024 is calculated as
Free Cash Flow (Q: Dec. 2024 ) | = | Cash Flow from Operations | + | Capital Expenditure |
= | -21.134 | + | -0.096 | |
= | -21.23 |
Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jasper Therapeutics (NAS:JSPR) Free Cash Flow Explanation
Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.
In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.
This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.
Therefore, as of Dec24, Jasper Therapeutics's Forward Rate of Return (Yacktman) % is
Forward Rate of Return (Yacktman) % (Dec24) | = | Normalized Free Cash Flow | / | Price | + | 5-Year EBITDA Growth Rate |
= | 0 | / | 21.38 | + | 0 | |
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.
Thank you for viewing the detailed overview of Jasper Therapeutics's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeetinder Singh Mahal | officer: Chief Operating Officer | C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
Velan Capital Master Fund Lp | other: See Footnote 1 | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Carlyle Group Inc. | 10 percent owner | C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Thomas G Wiggans | director | |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Ron Martell | director, officer: President, CEO & Director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Herb Cross | officer: Chief Financial Officer | 3061 ZANKER RD, SAN JOSE CA 95134 |
Scott C. Brun | director | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Edwin Jonathan Tucker | officer: Chief Medical Officer | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
Anna Louise French | director | C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
Kurt Von Emster | director, 10 percent owner | 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
Qiming U.s. Healthcare Fund Ii, L.p. | 10 percent owner | 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Mark Mcdade | 10 percent owner | C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040 |
Qiming U.s. Healthcare Gp Ii, Llc | 10 percent owner | 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
From GuruFocus
By Marketwired • 06-17-2024
By Marketwired • 10-14-2024
By Marketwired • 05-30-2024
By Marketwired • 06-14-2024
By Marketwired • 02-25-2025
By Marketwired • 08-13-2024
By Marketwired • 09-10-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 02-04-2025
By Marketwired • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.